(Q37278373)

English

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

scientific article published on 26 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. (English)

1 reference

Europe PubMed Central

19 August 2017

Adaptive radiation therapy

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Li-Yan Khor

1

1 reference

Europe PubMed Central

19 August 2017

Kyounghwa Bae

2

1 reference

Europe PubMed Central

19 August 2017

Rebecca Paulus

3

1 reference

Europe PubMed Central

19 August 2017

Tahseen Al-Saleem

4

1 reference

Europe PubMed Central

19 August 2017

M Elizabeth Hammond

5

1 reference

Europe PubMed Central

19 August 2017

David J Grignon

6

1 reference

Europe PubMed Central

19 August 2017

Mingxin Che

7

1 reference

Europe PubMed Central

19 August 2017

Varagur Venkatesan

8

1 reference

Europe PubMed Central

19 August 2017

Roger W Byhardt

9

1 reference

Europe PubMed Central

19 August 2017

Marvin Rotman

10

1 reference

Europe PubMed Central

19 August 2017

Gerald E Hanks

11

1 reference

Europe PubMed Central

19 August 2017

Howard M Sandler

12

1 reference

Europe PubMed Central

19 August 2017

Alan Pollack

13

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

26 May 2009

1 reference

Europe PubMed Central

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

19 August 2017

27

1 reference

Europe PubMed Central

19 August 2017

19

1 reference

Europe PubMed Central

19 August 2017

3177-3184

1 reference

Europe PubMed Central

19 August 2017

Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Interaction between the retinoblastoma protein and the oncoprotein MDM2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Mapping of the p53 and mdm-2 interaction domains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

6 September 2017

Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

14 September 2017

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

14 September 2017

Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

14 September 2017

Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

26 June 2018

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

3 September 2018

Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

3 September 2018

Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

3 September 2018

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716939

3 September 2018

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19470936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.8267

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37278373&oldid=2131042320"